- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John Theurer Cancer Center, Hackensack University Medical Center | Strategic Alliance Partners
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 803-bed nonprofit teaching and research hospital, was Bergen County’s first hospital founded in 1888. It was also the first hospital in New Jersey and second in the nation to become a Magnet®-recognized hospital for nursing excellence, receiving its sixth consecutive designation from the American Nurses Credentialing Center. The academic flagship of the Hackensack Meridian Health network, Hackensack University Medical Center is Nationally-Ranked by U.S. News & World Report 2022-2023 in four specialties, more than any other hospital in New Jersey. The hospital is home to the state's only nationally-ranked Urology and Neurology & Neurosurgery programs, as well as the best Cardiology & Heart Surgery program. It also offers patients nationally-ranked Orthopedic care and one of the state’s premier Cancer Centers (John Theurer Cancer Center at Hackensack University Medical Center). Hackensack University Medical Center also ranked as High-Performing in conditions such as Acute Kidney Failure, Heart Attack (AMI), Heart Failure, Pneumonia, chronic obstructive pulmonary disease (COPD), Diabetes and Stroke. As well as High Performing in procedures like Aortic Valve Surgery, Heart Bypass Surgery (CABG), Colon Cancer Surgery, Lung Cancer Surgery, Prostate Cancer Surgery, Hip Replacement and Knee Replacement. Named to Newsweek’s World’s Best Hospitals 2023 list, Hackensack University Medical Center is also the recipient of the 2023 Patient Safety Excellence Award™ by Healthgrades as well as an “A” Hospital Safety Grade from The Leapfrog Group. This award-winning care is provided on a campus that is home to facilities such as the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Donna A. Sanzari Women’s Hospital and the Joseph M. Sanzari Children’s Hospital, ranked #1 in the state and top 20 in the Mid-Atlantic Region in the U.S. News & World Report’s 2022-23 Best Children’s Hospital Report. Additionally, the children’s nephrology program ranks in the top 50 in the United States. Hackensack University Medical Center is also home to the Deirdre Imus Environmental Health Center and is listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. Our comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development. The hospital has embarked on the largest healthcare expansion project ever approved by the state: Construction of the Helena Theurer Pavilion, a 530,000-sq.-ft., nine-story building, which began in 2019. A $714.2 million endeavor, the pavilion is one the largest healthcare capital projects in New Jersey and will house 24 state-of-the-art operating rooms with intraoperative MRI capability, 50 ICU beds, and 175 medical/surgical beds including a 50 room Musculoskeletal Institute.
Latest from John Theurer Cancer Center, Hackensack University Medical Center
Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy
March 09, 2022
Video
Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.
Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL
March 08, 2022
Video
Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.
Investigators Tackle the Untapped Potential of Personalized Medicine
February 26, 2022
Article
Improving patient outcomes is top of mind for investigators at John Theurer Cancer Center in Hackensack, New Jersey.
Oral Decitabine Plus Cedazuridine Combo Shows Promise in Lower-Risk MDS
January 12, 2022
Article
James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.
Dr. Feldman on Adding Etoposide to Brentuximab Vedotin/CHP in Peripheral T-Cell Lymphomas
January 10, 2022
Video
Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.
Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma
January 10, 2022
Video
Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.
Dr. McCloskey on the Utility of Decitabine Plus Cedazuridine in Lower-Risk MDS
January 07, 2022
Video
James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.
Dr. Leslie on Axi-Cel Vs SOC in Relapsed/Refractory Large B-Cell Lymphoma
January 07, 2022
Video
Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.
Dr. Vaidya on Advances in the Management of Endometrial Cancer
November 11, 2021
Video
Ami P. Vaidya, MD, discusses advances in the management of endometrial cancer.
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
October 11, 2021
Podcast
Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.
Novel Agents Gain Traction in the Treatment of Multiple Myeloma
August 06, 2021
Article
Noa Biran, MD, discusses her predictions for where the field of multiple myeloma is headed as well as some of these agents that have generated excitement for patient populations that are currently an unmet need.
Dr. Goy on the Durability of Response With Brexucabtagene Autoleucel in MCL
May 06, 2021
Video
Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.
Dr. Goy on the Potential Utility of Liso-Cel in MCL
April 19, 2021
Video
Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.
Single Port Robotic ENT Surgery Takes Throat and Mouth Tumor Treatment to ‘A New Level’
April 14, 2021
Article
Innovative robotic technology helps to improve surgical outcomes and safety for patients while advancing the field of ENT surgery.
Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL
April 08, 2021
Video
Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.
Dr. Ip on the Utility of Investigational Treatments for COVID-19 in Oncology
March 31, 2021
Video
Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.
Dr. Ip on Remaining Questions With the COVID-19 Vaccine in Oncology
March 23, 2021
Video
Andrew Ip, MD, MS, discusses remaining questions with the COVID-19 vaccine in patients with cancer.
Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL
March 12, 2021
Video
Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.
Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC
March 11, 2021
Article
Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.
Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types
January 25, 2021
Article
Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.